Patents Examined by Brenda L. Coleman
  • Patent number: 11447466
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: Y is Formula (II), or Formula (III); R1, R2, R2a, R2b, R2c, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: September 20, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Tasir Shamsul Haque, Brian K. Whiteley, John L. Gilmore
  • Patent number: 11446312
    Abstract: The present invention relates to a compound having the structure of Formula (I) for use in the prevention or treatment of a blood disorder, in particular by the modulation of von Willebrand factor levels. A nutraceutical product or food product comprising the compound of the invention 5 are also provided.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: September 20, 2022
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Jasna Klicic Badoux, Amy Melissa Pooler, Claus Rieker
  • Patent number: 11439626
    Abstract: Disclosed herein are controlled release compositions comprising riluzole and the uses thereof.
    Type: Grant
    Filed: September 19, 2020
    Date of Patent: September 13, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventor: Ana Pereira
  • Patent number: 11440907
    Abstract: The present invention provides compounds of Formula I?, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: September 13, 2022
    Assignees: MERCK PATENT GMBH, VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Henry Yu, Michael Clark, Guy Bemis, Michael Boyd, Kishan Chandupatla, Philip Collier, Hongbo Deng, Huijun Dong, Warren Dorsch, Russell R. Hoover, Mac Arthur Johnson, Jr., Shashank Kukarni, Marina Penney, Steven Ronkin, Darin Takemoto, Qing Tang, Nathan D. Waal, Tiansheng Wang, David J. Lauffer, Pan Li
  • Patent number: 11426465
    Abstract: The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: August 30, 2022
    Assignee: Redwiid Bioscience, Inc.
    Inventors: Romas Alvydas Kudirka, Aaron Edward Albers, Robyn M. Barfield, David Rabuka
  • Patent number: 11420981
    Abstract: The invention discloses a process for the preparation of maytansinoid esters of formula (I) comprising a thiol or disulphide group wherein R1, R4 and R5 and the asterisk are as defined in the description, by reacting maytansinol with an enantiopure alpha-azido acid, followed by reduction of the azido group and reacting the obtained amino-ester with a compound of formula (IX) (IX) R3—S—S—X—COOH wherein X and R3 are as defined in the description, or with a reactive derivative thereof and optionally reducing the obtained disulfide-containing maytansinoid ester to give a maytansinoid ester wherein R1 is a —X—SH group.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: August 23, 2022
    Assignee: Indena S.P.A.
    Inventors: Gabriele Fontana, Ruggero Beretta, Maurizio Taddei, Salvatore Princiotto
  • Patent number: 11414425
    Abstract: This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an ?5-containing GABAA receptor agonist (e.g., an ?5-containing GABAA receptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease (AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an ?5-containing GABAA receptor agonist (e.g.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: August 16, 2022
    Assignee: AGENEBIO, INC.
    Inventors: Belew Mekonnen, John A. Butera, Jianxing Huang, Hemantbhai Patel, Qin Jiang, Robert Jason Herr, Emily Elizabeth Freeman, Nicholas James Mayhew
  • Patent number: 11406645
    Abstract: The present invention provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: August 9, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Jun Qi, Minoru Tanaka
  • Patent number: 11407783
    Abstract: A triptolide derivative, a preparation method therefor, and a method for use thereof are described. The triptolide derivative has the structure as shown in general formula I, and the definition of each substituent is as described in the description and claims. The triptolide derivative has improved immunosuppressive activity and anti-tumor activity, low toxicity and high safety, thus having good development and application prospects.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: August 9, 2022
    Assignees: CINKATE PHARMACEUTICAL INTERMEDIATES CO., LTD., CINKATE PHARM TECH (SHANGHAI) CO., LTD.
    Inventors: Fei Xiao, Bo Qiu, Peng Zhang
  • Patent number: 11401266
    Abstract: The present invention is directed to processes for preparing a diazepane compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is further directed to crystalline forms of this diazepane compound and pharmaceutical compositions thereof.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: August 2, 2022
    Assignee: Merck Sharp & Dohme (UK) Ltd.
    Inventors: Carl A. Baxter, Faye Sheen
  • Patent number: 11400095
    Abstract: The invention provides substituted imidazo[1,5-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidine compounds described herein include substituted 2,4-dimethyl-N-phenylimidazo[1,5-a]pyrimidine-8-carboxamide compounds and variants thereof.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: August 2, 2022
    Assignee: Bial—R&D Investments, S.A.
    Inventors: Renato T. Skerlj, Peter T. Lansbury, Andrew C. Good, Elyse Marie Josee Bourque
  • Patent number: 11389440
    Abstract: The present invention provides for a method of treating cancer and/or reducing proliferation of cancer cells, the method comprising administering to a subject in need of such treatment a composition comprising a PIM kinase inhibitor that exhibits changes in expressed RNA or ribosomal binding proteins in combination with a compound that inhibits autophagy.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: July 19, 2022
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    Inventors: Charles J. Bieberich, Xiang Li
  • Patent number: 11389457
    Abstract: The present invention relates to a method for preventing transmission of influenza, wherein said method comprises administering an effective amount of a compound to a patient having an influenza virus infection, herein referred to as “index patient”, wherein the compound has one of the formulae (I) and (II), or its pharmaceutically acceptable salt. The compound to be used in the present invention reduces infectivity of the influenza virus of the index patient, and therefore, reduces the risk of the index patient to trigger an influenza epidemic or an influenza pandemic as compared to a control patient.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: July 19, 2022
    Assignees: Hoffmann-La Roche Inc., Shionogi & Co., Ltd.
    Inventors: Takeshi Noshi, Takahiro Noda, Ryu Yoshida, Takao Shishido, Kaoru Baba, Aeron C. Hurt, Leo Yi Yang Lee, Steffen Wildum, Klaus Kuhlbusch, Barry Clinch, Jan Michal Nebesky, Annabelle Lemenuel, Wendy S. Barclay, Jean-Eric Charoin, Yoshinori Ando
  • Patent number: 11382921
    Abstract: Disclosed is a use of 5?-androstane-3?,5,6?-triol, an analogue, a deuterated derivative, and a pharmaceutically acceptable salt thereof in manufacture of a medicament for the treatment of hemorrhagic stroke in a patient. The hemorrhagic stroke is intracerebral hemorrhage or subarachnoid hemorrhage.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 12, 2022
    Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD
    Inventors: Guangmei Yan, Yijun Huang, Wei Yin, Suizhen Lin
  • Patent number: 11376260
    Abstract: Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: July 5, 2022
    Assignee: Genentech, Inc.
    Inventors: Aleksandr Kolesnikov, Steven Do
  • Patent number: 11377429
    Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: July 5, 2022
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Patent number: 11377428
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: July 5, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
  • Patent number: 11370764
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: June 28, 2022
    Assignee: Rigel Pharmaceuticals Inc.
    Inventors: Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
  • Patent number: 11370765
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: June 28, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
  • Patent number: 11370762
    Abstract: The present invention relates to a vinylarene deriv. which modulates or inhibits the enzymic activity of indoleamine 2,3-dioxygenase 1 (IDO-1), and the use thereof, and further relates to a vinylarene deriv. and the use thereof. The vinylarene deriv. and its stereoisomer, cis- or trans-isomer, or tautomer thereof and pharmaceutically acceptable salt thereof, has an IDO-1 enzyme inhibitory activity, and is expected to provide brand new therapeutic methods and schemes for related diseases caused by IDO enzymes.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 28, 2022
    Assignee: SHENYANG RESEARCH INSTITUTE OF CHEMICAL INDUSTRY CO., LTD.
    Inventors: Zhaojin Ran, Baoshan Chai, Wanqiu Wang, Haihong Guang, Jiayuan Jiao